Summary
The AI claims multiple drug-drug interaction effects (increasing carbamazepine/phenobarbital/phenytoin/valproate/lamotrigine/topiramate levels and related adverse effects) that are not supported by the supplied FDA label excerpts. The label provided for lacosamide primarily discusses effects of strong CYP inhibitors on lacosamide exposure and caution with drugs affecting cardiac conduction, not the direction or outcomes of interactions with those other antiseizure drugs.
Category Scores
Accurate Statements
VIMPAT can interact with other antiepileptic medications.
Label section 7 (Drug Interactions) addresses concomitant medications affecting cardiac conduction (including those prolonging PR interval) and strong CYP3A4/CYP2C9 inhibitors affecting VIMPAT exposure; however, the claim is broad and not specific to the listed antiepileptics.
Unsupported Statements
Lacosamide can increase the levels of carbamazepine.
No label excerpt in the prompt states that lacosamide increases carbamazepine levels.
Increased carbamazepine levels with lacosamide may lead to increased side effects such as dizziness and drowsiness.
No label excerpt provided links lacosamide to increased carbamazepine levels or to dizziness/drowsiness via that mechanism.
Lacosamide can increase the levels of phenobarbital.
No label excerpt in the prompt states that lacosamide increases phenobarbital levels.
Increased phenobarbital levels with lacosamide may lead to increased side effects such as sedation and respiratory depression.
No label excerpt provided links lacosamide to increased phenobarbital levels or to sedation/respiratory depression via that mechanism.
Lacosamide can increase the levels of phenytoin.
No label excerpt in the prompt states that lacosamide increases phenytoin levels.
Increased phenytoin levels with lacosamide may lead to increased side effects such as dizziness and drowsiness.
No label excerpt provided links lacosamide to increased phenytoin levels or to dizziness/drowsiness via that mechanism.
Lacosamide can increase the levels of valproate.
No label excerpt in the prompt states that lacosamide increases valproate levels.
Increased valproate levels with lacosamide may lead to increased side effects such as liver damage and pancreatitis.
No label excerpt provided links lacosamide to increased valproate levels or to liver damage/pancreatitis via that mechanism.
Lacosamide can increase the levels of lamotrigine.
No label excerpt in the prompt states that lacosamide increases lamotrigine levels.
Increased lamotrigine levels with lacosamide may lead to increased side effects such as rashes and allergic reactions.
No label excerpt provided links lacosamide to increased lamotrigine levels or to rashes/allergic reactions via that mechanism.
Lacosamide can increase the levels of topiramate.
No label excerpt in the prompt states that lacosamide increases topiramate levels.
Increased topiramate levels with lacosamide may lead to increased side effects such as kidney stones and cognitive impairment.
No label excerpt provided links lacosamide to increased topiramate levels or to kidney stones/cognitive impairment via that mechanism.
Lacosamide can enhance the effects of other antiepileptic medications such as valproate and lamotrigine.
No label excerpt provided states lacosamide enhances effects of valproate or lamotrigine.
Enhancement of other antiepileptic medications’ effects with lacosamide may increase the risk of side effects.
No label excerpt provided supports a general mechanism of enhancing other antiseizure drug effects by lacosamide.
Regular monitoring of blood levels of lacosamide and other medications can help minimize the risk of side effects.
The supplied label excerpts do not recommend routine blood-level monitoring of lacosamide and other antiseizure drugs.
Adjusting doses of lacosamide and other medications as needed can help minimize the risk of side effects.
While label excerpts discuss titration and dose reduction for VIMPAT exposure in specific contexts (e.g., hepatic/renal impairment with dosing guidance and caution with cardiac conduction drugs), the prompt does not support a directive to adjust doses of 'other medications' based on drug-level monitoring to minimize side effects.
Contradictions
Important Omissions
Concomitant medication guidance specific to the provided label (e.g., caution with drugs that prolong PR interval or affect cardiac conduction) and the interaction context of strong CYP3A4/CYP2C9 inhibitors affecting lacosamide exposure.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The AI attributes specific pharmacokinetic interaction claims (increasing levels of multiple antiseizure drugs) and specific downstream adverse effects to those increased levels. None of these mechanisms are supported by the supplied label excerpts, making the content likely unreliable for safety and monitoring decisions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple drug-drug interaction claims (increasing other drugs’ levels and resulting adverse effects) are unsupported by the provided FDA label excerpts for lacosamide.
Suggested Improvement
Limit interaction statements to what the provided label supports: caution with concomitant drugs affecting cardiac conduction (e.g., those that prolong PR interval/slow AV conduction) and dose reduction considerations in patients taking strong CYP3A4/CYP2C9 inhibitors affecting lacosamide exposure; avoid asserting level increases for carbamazepine, phenytoin, phenobarbital, valproate, lamotrigine, or topiramate unless supported by the actual label text.